AI Article Synopsis
- The discovery of tumor antigens like D393-CD20 is crucial for developing new cancer diagnostics and therapies.
- CD8+ T lymphocytes are key players in the immune response against cancer, and this study focuses on using them against the D393-CD20 antigen in the RAMOS cell line.
- The findings indicate that TCD8+ lymphocytes targeting D393-CD20 can effectively induce apoptosis in malignant B-lymphocytes, suggesting its potential as a target for immunotherapy.
Article Abstract
The effective discovery of clinically relevant tumor antigens holds a fundamental role for the development of new diagnostic tools and anticancer immunotherapies. D393-CD20 mRNA is absent from normal resting B cells but present in various malignant or transformed B cells. CD8+T lymphocytes play a central role in immunity to cancer. In this study, we want use from T CD8+ against D393-CD20 for effect in RAMOS cell line. After isolation and expanding of specific TCD8 + Lymphocyte against D393-CD20 antigen, for examining the effect of specialized T lymphocyte clone of D393-CD20 antigen on RAMOS cell line, we co-cultured them together, and the rate of apoptosis were examined by flow cytometry and cytotoxicity techniques by using MTT technique. We observed that specialized TCD8+ lymphocyte of D393-CD20 antigen can induce apoptosis in malignant B-lymphocytes, and this antigen can be a proper target for immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852797 | PMC |
| http://dx.doi.org/10.31557/APJCP.2019.20.8.2563 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preliminary In Vitro Effects of CD8+ T Lymphocyte Specific for the CD20 Alternative Splicing D393-CD20 Peptide Expressed on Burkitt Lymphoma Cells.
Asian Pac J Cancer Prev
August 2019
National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Article Synopsis
- The discovery of tumor antigens like D393-CD20 is crucial for developing new cancer diagnostics and therapies.
- CD8+ T lymphocytes are key players in the immune response against cancer, and this study focuses on using them against the D393-CD20 antigen in the RAMOS cell line.
- The findings indicate that TCD8+ lymphocytes targeting D393-CD20 can effectively induce apoptosis in malignant B-lymphocytes, suggesting its potential as a target for immunotherapy.
CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.
Int J Cancer
July 2015
INSERM UMR1098, F25020 Besançon cedex, France; Université de Franche-Comté, F25020 Besançon cedex, France; EFS Bourgogne Franche-Comté, F25020 Besançon cedex, France.
Cancer-specific splice variants gain significant interest as they generate neo-antigens that could be targeted by immune cells. CD20, a membrane antigen broadly expressed in mature B cells and in B cell lymphomas, is subject to an alternative splicing named D393-CD20 leading to loss of membrane expression of the spliced isoform. D393-CD20 expression is detectable in transformed B cells and upregulated in various lymphoma B cells.
View Article and Find Full Text PDFThe need for markers and predictors of Rituximab treatment resistance.
Exp Dermatol
April 2014
Department of Dermatology, University Medical Center Freiburg, Freiburg, Germany; BIOSS Centre for Biological Signalling Studies, Freiburg, Germany; Department of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany.
CD20-specific antibodies show remarkable therapeutic efficacy in B-cell malignancy and autoimmune diseases, but due to the occurrence of a significant treatment resistance, a critical, unmet need for improving B-cell-depleting approaches remains. A CD20 transcript variant (D393-CD20) appears to be associated with Rituximab treatment resistance in malignant B cells, but is lacking in patients with autoimmune dermatoses as shown by Gamonet et al. While CD20-specific factors certainly play a major role in the pathogenesis of Rituximab treatment resistance, the D393-CD2 transcript may greatly facilitate the development of clinical markers for monitoring the therapy in B-cell malignancies and (auto)antibody-mediated diseases.
View Article and Find Full Text PDFLack of expression of an alternative CD20 transcript variant in circulating B cells from patients with pemphigus.
Exp Dermatol
January 2014
Inserm UMR 1098, Etablissement Français du Sang Bourgogne-Franche Comté, Besançon, France.
We have identified a spliced mRNA transcript of CD20 (named D393-CD20) which was associated with resistance to RTX in primary B cell from patients with lymphoma and leukaemia. In the present work, we wished to investigate whether D393-CD20 variant was expressed by B cells from patients with pemphigus. Ten patients with bullous pemphigoid and twenty-five patients with pemphigus were included.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!